



Webinar: Maintaining Immune Health in the Face of COVID-19 and Future Viruses

Presentation Slides: George Kuchel, MD, FRCP, AGSF

What is it about immune aging that makes older adults so vulnerable to COVID-19?


George A. Kuchel, MD, FRCP, AGSF Travelers Chair in Geriatrics and Gerontology Director, UConn Center on Aging, University of Connecticut Chief, Geriatric Medicine, UConn Health <u>kuchel@uchc.edu</u>




AFAR Webinar, May 12 2020

Vulnerability of Older Adults to COVID-19:

Nearly all aspects of immune response and host defense are impacted by aging







CENTER ON AGING

Vulnerability of Older Adults to COVID-19:

Impact of Immune Aging on Ability to Handle Familiar and Unfamiliar Pathogens



Vulnerability of Older Adults: Must consider dynamic processes involving resilience mechanisms needed to maintain homeostasis in the face of a stressor (pathogen)



Potential Role of Another Geroprotector (Metformin) in Reducing Onset and Progression of Multiple Chronic Diseases TAME Trial (Targeting Aging with Metformin)

Inclusion Criteria: Age 65-80, nondiabetic, some comorbidities allowed; n = 3,000 Double blind placebo-controlled trial


Primary Outcome:TIME TO MAJOR DISEASES (FDA)Secondary Outcome:FUNCTIONAL AGINGTertiary Outcomes:BIOMARKERS (NIA)

Impact of Metformin on Flu Vaccine Responses (VEME-AFAR/NIA, Jenna Bartley, PhD - UConn)



Potential Role of One Geroprotector (RTB101) in Reducing Respiratory Infections

Phase 2b: RTB101 reduces the incidence of respiratory tract infections caused by multiple viruses including coronavirus



res**TOR**bio

